Annual Report • Apr 28, 2017
Annual Report
Open in ViewerOpens in native device viewer

(unified registration number 40003306807)
PREPARED ACCORDING TO INTERNATIONAL FINANCIAL REPORTING STANDARDS ADOPTED BY THE EUROPEAN UNION AND INDEPENDENT AUDITORS' REPORT
Riga, 2017
| General information on the Group parent company | 3 - 4 |
|---|---|
| Management Report | 5 - 6 |
| Statement of the Board's Responsibilities | 7 |
| Independent Auditors' Report | 8 - 13 |
| Consolidated financial statements: | |
| Consolidated Statement of Profit or Loss and Other Comprehensive Income | 14 |
| Consolidated Statement of Financial Position. | 15 - 16 |
| Consolidated Statement of Changes to Shareholders' Equity | 17 |
| Consolidated Statement of Cash Flows | 18 |
| Notes to the consolidated financial statements | 19-44 |
name of the group parent company: Latvijas jūras medicīnas centrs
LEGAL STATUS OF THE GROUP PARENT COMPANY: Joint Stock Company
REGISTRATION OF THE GROUP PARENT COMPANY: Registered with the Enterprise Register of the A
rt Collection of the CE Ament 2014 · Becistration number: 40003306807 REGISTRATION OF THE GROUP PARENT Otion of the GROUP
LEGAL ADDRESS OF THE GROUP PARENT COMPANY: Patversmes iela 23, Riga, LV – 1005, Latvia
Hospital activities (86.10) Hospital activities (86.10)
Retail sale of medical and orthopaedic goods in specialised stores (47.74)
Retail sale of medical and orthopaedic goods in specialised stores (47. Other education n.e.c. (85.59) General medical practice activities (86.21) Special medical practice activities (86.22) Dental practice activities (86.23) Other human health activities (86.90) Residential nursing care activities (87.10) Other residential care activities (87.90) Other residential care activities without accommodation n.e.c. (88.99)
Other social work activities without accommodation n.e.c. (88.99)
1990 (1994) 1990 (1994) Physical well-being activities (96.04) Other personal service activities n.e.c. (96.09)
SHARES OF THE GROUP PARENT COMPANY: 800 000 public name shares with a nominal value of EUR 1.40 ISIN code:LV0000100741
llze Birka 17.50% Mārtiņš Birks 17.50% Jānis Birks 12.80% Guna Švarcberga 10.36% Ilze Aizsilniece 8.82% Adomas Navickas 6.85%
From 28 April 2010 until the date of signing these financial statements
Mārtiņš Birks - Chairperson of the Council Viesturs Silinš - Council Member Ineta Gadzjus - Council Member Jevgenijs Kalējs - Council Member Uldis Osis - Council Member
From 1 May 2014 until the date of signing these financial statements, unless noted otherwise
Jānis Birks - Chairperson of the Board Juris Imaks - Board Member Vita Svarcberga - Board Member until 6 June 2016 Anatolijs Ahmetovs - Board member since 13 January 2017
Neirožu Klīnika SIA Neirozu Kimika Une parent company: 50.40% Registration number: 40003461335 Registration number: 40003461000 rouser: 16 February 2004
Registration with the Commercial Register: 10 February 2004 Registration with the Oonnospekts 48, Jurmala, LV 2015,
REPORTING YEAR: 1 January 2016 – 31 December 2016
KPMG Baltics SIA Licence No 55 Vesetas iela 7 Riga, LV-1013 Latvia
Certified auditor in charge: Armine Movsisjana Certificate No. 178
AS Latvijas Jūras medicīnas centrs (LJMC or the Company) is a certified and advanced private medical facility AS Latvijas Juras medicinas centrs (LJMC of the Univers) 18 december 2011:e at 23 Patversmes iela,
available to everyone, which consists of Sarkania Ambuiatory Healthean Diag available to everyone, which consists of Salkanians Hoyoital and Northern Diagnostics Centre 26
Riga, Central Hospital at 23 Patversmes iela, Riga, Vecmilgravis 10 Molidas ie Riga, Central Hospital at 23 Patvelsmes tela, Riga, vechingth riset Copente at 10 Melidas iela, Kiga. In 2016, the Vecmilgravja 5.inlija, Kiga, and Vechiligravis I rimal J reirožu klinika SIA (hereinafter together - the Baltie Secondary list of average total number of employees of Lawc and instrument on the Baltic Secondary list of Group) was 380. The Shares of A/S Latvijas ouras mechodiae www.dimari.lv.sIA Neirožu
Nasdaq Riga. Full information on the Group is provided on: www.dimiani.lv.slipping in Jur Nasdaq Riga. Full information on the Group is provided on medical services in the clinic in Jurmala.
klīnika offers psychotherapy and other secondary ambulatory medical servi
On 5 September 2013, A/S Latvijas Jūras medicīnas centrs became enlisted among the medical facilities. On 5 September 2013, A/S Latvias Julias Incuration services nedical tourism services. Namely, LIMC approved by the Health Inspectorate of Latvia, which provides an outlook to the overall Latvian health provides medical tourism services as a reliable particle have institutions which have been registered with the heath care care system because the list only menues those nearneare instructions has been carried out in the health care institution during the past three years.
In 2013, LJMC Northern Diagnostics Centre received from DNV Certification OY/AB Finland quality In 2013, LIMC Northern Diagnostics and radiology diagnostics valid until 14 March 2016. This certificate ISO 9001:2008 in lunctional diagliosurs and radio until 15 September 2018. In 2017, LJMC will
certificate was renewed at the beginning of 2016 to be valid units o certificate was renewed at the beginning of the ro to ards in other structural units of the centre.
LJMC has accredited Clinical Diagnostics Laboratory at 23 Patversmes iela with the Latvian National Accreditation Bureau.
LJMC has signed cooperation agreements with all health insurance companies operating in Latvia.
In 2016, LJMC and SIA Neirožu klīnika signed agreements with National Health Service for provision of state paid medical services in the amount funded by the budget for 2016.
One of the focus areas for 2016 was the attraction of patients living abroad. LJMC employs excellent Latvian doctors and knowledgeable medical staff, so the quality of medical examinations is high and competitive also beyond the borders of Latvia. It is validated by the growing number of foreign patients and the fact that LJMC is entered in the registry of medical tourism service providers maintained by the Health Inspectorate of Latvia. Is encream at will continue attracting medical tourists from the EU by improving its service offering and actively advertising paid medical services for local inhabitants. To attract more foreign and local patients in 2017 LJ MC will continue making investments to implement innovative solutions for providing medical services, improve qualification of staff in servicing patients, continuing the state policy in re-profiling of hospitals to ambulatory healthcare institutions. In 2017 the Company plans to decrease its shareholding in SIA Neirožu klīnika.
In 2013, LJMC completed a significant 3 year investment project of EUR 2.3 million, using also EBRD support. The above investment project included a renovation of the old building complex of Latvijas Jūras medicīnas centrs and improvement of its territory according to the standards of modern medical facilities and investments were made in new medical equipment establishing Sarkandaugavas Ambulatoras Veselibas Aprūpes Centrs (SAVAC). This way Latvijas Jūras medicīnas centrs is actively promoting its competitiveness on the Baltic medical market, attracting patients from the Baltic countries and the rest of the EU by providing high quality medical services. Since Sarkandaugavas Ambulatoras Veselības Aprūpes Centrs (SAVAC) was established the number of new clients increased by 25%. The partial re-profiling from in-patient services has already increased, and is expected to continue to increase, the effectiveness of operation of LJMC by enabling maximum use of the resources available to the centre and providing a higher quality medical care to patients.
On 24 March 2016, a construction contract was singed with SLA Selva būve for reconstruction of the building On 24 March 2016, a construction of Radiology Department iel. Riga. The contractual owned by LJMC and construction of Kadiology Department of the with the completion progress.
amount is EUR 920 792 excluding VAT. Construction work with he completion progress amount is EUR 920 792 excluding VAT. Collist action work with be state of these financial statements,
of the project and based on a payment schedule set in the State, Constru of the project and based on a payment schedule seculture. I w the State Construction Control Office. The the building was prepared for completion to be appear in the been amended.
In the 12 months of 2016, the Group operated in accordance with the budget approved for 2016. Profit of the Group is EUR 2 753.
In the twelve months of 2016, LJMC operated in accordance with the budget approved for 2016: the revenue In the twelve months of 2016, LJMC operated in accondantle with the 38%, compared to the estimates for the plan was fulfilled at 106.27% and the expense primarily due to the business combination with SIA Neirožu klīnika and changes in the fair value of acquired assets.
The Group continues to intensive investment policy, which is almed at inceasing the The Group continues to Timplement an Tinestice Investment polioy of investment for 2017 is EUR 500 000.
The Group continues carrying out activities seeking to limit the negative impact of potential financial risks on The Group continues carrying out actimate socuriting a set of control and analysis measures.
Financial assets exposed to credit risk are mostly cash, trade receivables and other receivables. Credit risk in Filiancial assets exposed to crear fisk are lardebtor control procedures and debt collection measures aiming to identify and solve any problems on a timely basis.
Liquidity risk is managed by the Group in line with the principle of prudence ensuring that appropriate credit Liquidity risk is managed by the Group in inthey fall due. The companies of the Group do not use loans.
No significant subsequent events have occurred from the reporting date to the date of these financial statements that would have a material impact on the financial position of the Group or require disclosures to be made in these consolidated financial statements.
Chairperson of the Board Board Member Juris Imaks Jānis Birks Board Member Anatolijs Ahmetovs 28 April 2017
The Board of AS Latvijas Jūras medicīnas centrs (hereinafter - the Company) is responsible for preparing the The Dodia of ho Eathyle statements of the Company and its subsidiary (hereinafter – the Group).
The financial statements on pages 14 to 44 were prepared based on accounting records and sources The "Internetitioner" on "pego" cial position of the Group as at 31 December 2016 and the results of its operations, and cash flows for the year then ended.
The consolidated financial statements were prepared in accordance with International Financial Reporting Standards (hereinafter – IFRS) as adopted by the European Union on a going concern basis. Appropriate accounting policies have been applied on a consistent basis. Prudent and reasonable judgments and estimates have been made by the management in the preparation of the financial statements.
The Board of the Company is responsible for the maintenance of a proper accounting system, safeguarding the Group's assets, and the prevention and detection of fraud and other irregularities in the Group. The Board is also responsible for compliance with laws of the Republic of Latvia.
Board Member Chairperson of the Board Juris Imaks Jānis Birks Board Member Anatolijs Abmetovs 28 April 2017

KPMG Baltics SIA Vesetas iela 7 Riga, LV-1013 Latvia
Telephone +371 67038000 +371 67038002 Telefax kpmg.com/lv
We have audited the accompanying consolidated financial statements of AS Latvijas Juras We have addited the accompanying ourisonationialiations ("the Group") set out on pages 14 to 44 of the accompanying consolidated Annual Report, which comprise:
In our opinion, the accompanying consolidated financial statements give a rue and fair view infour opinion, the accompanying consolidation of AS Latvijas Jūras medicīnas centrs and its of the consolidated "imanola" position and of its consolidated financial performance and its Subsidianes as at of Dosor the year then ended in accordance with International Financial Reporting Standards as adopted by the European Union (IFRSs).
In accordance with the 'Law on Audit Services' of the Republic of Latvia we conducted our in dooordance with International Standards on Auditing adopted in the Republic of Latvia (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibility for the Audit of the Consolidated Financial Statements section of our report.
We are independent of the Group in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and independence requirements included in the 'Law on Audit Services' of the Republic of Latvia that are relevant to our audit of the consolidated financial statements in the Republic of Latvia. We have also fulfilled our other professional ethics responsibilities and objectivity requirements in accordance with the IESBA Code and the 'Law on Audit Services'of the Republic of Latvia.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters are those matters that, in our professional judgment, were of most Rey addit matters' are those matters thancial statements of the current period. These Significance in our addit of the context of our audit of the consolidated financial statements
matters were addressed in the context of our audit of the consolidated financi matters were addressed in the context of our addit of the occurrent opinion on these matters.
| Recognition of revenue from medical services | |||
|---|---|---|---|
| Key audit matter | Key audit matter | ||
| Revenues from ambulatory medical services (including services covered by insurance) in the consolidated financial statements as at and for the year ended 31 December 2016: EUR 5.73 million. We refer to the consolidated financial statements: Note 2n |
Our procedures included, among others: · Performing a walkthrough of revenue from medical services recognition process and testing design and implementation of controls over revenue recognition including the comparison of monthly cash register reports to amounts recognized in the financial statements. Performing analytical procedures and journal |
||
| (accounting policy) and Note 4 (financial disclosures). The Group offers a wide variety of healthcare services with complex pricing structure. 52% of the revenues from medical services represent financing received from the National Health Service. As the state funding is allocated to particular periods, there is a risk of manipulations in the timing and amount of revenue recognized in |
entry testing in order to identify and test potential risk of misstatement arising from management override of controls. We performed substantive analytical procedures to consider trends that could indicate material misstatements, and reconciled recognized revenue with reports from cash registers as well as obtained external turnover conformations received from the National Health Service and insurance companies. Remaining revenue has been tested against payments received on a sample basis. |
||
| order utilize the available funds more efficiently. Furthermore, remuneration of professional staff is tied to the recognized and may revenues further incentive to create manipulate revenues. As a consequence, there is an increased risk of misstatement in revenue balances, either by fraud or error, including through potential override of controls by management. |
The timeliness of cash payments from all of the main customer streams has been corroborated to provide additional audit evidence for accuracy of revenue recognition. We obtained a breakdown of cash settlements to verify the recoverability of debtors as at 31 December 2016. We also performed cut-off testing for a sample of revenue recognized shortly before and after year-end to obtain audit evidence that revenue is recognised in the correct period. |

| Completeness of remuneration expenses | |||
|---|---|---|---|
| Key audit matter | Our response | ||
| Remuneration expenses in the consolidated financial statements as at and for the year ended 31 December 2016: EUR 2.96 million. We refer to the consolidated financial statements: Note 2m (accounting policy) and Notes 5, 6 and 23 (financial disclosures). Nearly 50% of Remuneration expenses for the year ended 31 December 2016 is comprised of variable pay that is calculated based on the volume and type of services provided by professional medical staff and rates set by the management or in the agreement with National Health Service for state funded services. The remuneration calculation process in the Group, which is inherently complex and involves multiple inputs, is not automated. This significantly increases the risk of error and led us to select completeness of remuneration expenses as a significant risk. |
Our procedures included, among others: Performing a walkthrough of variable pay calculation by recalculating pay for different kinds of ambulatory medical services. Performing substantive analytical procedures by setting expectation for variable pay for services funded by the National Health Service. The inputs used in the analytical procedures included list of services provided throughout the reporting year obtained from the National Health Service and applied rates set by the management to these services. As variable pay rates for family doctors are determined by the National Health Service, we have agreed the remuneration expenses to reports from the National Health Service on a sample basis. Variable pay for paid medical services was recalculated on a sample basis. We have compared supporting calculations for selected employees to the report for total paid medical services provided throughout the year to test the completeness of variable pay. We have also compared the variable pay rates used in calculations to rates approved by the management and referred to in the employment contracts. |
The respective prior period information is based on the Group's consolidated financial statements for the year ended 31 December 2015, which was audited by another audit firm who expressed an unqualified opinion on these consolidated financial statements in their auditors' report dated 9 May 2016.

The Group's management is responsible for the other information. The other information comprises:
Our opinion on the consolidated financial statements does not cover the other information included in the consolidated Annual Report, and we do not express any form of assurance conclusion thereon, except as described in the Other Reporting Responsibilities in Accordance with the Legislation of the Republic of Latvia section of our report.
In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.
If, based on the work we have performed and in light of the knowledge and understanding of the Group and its environment obtained in the course of our audit, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
In addition, in accordance with the 'Law on Audit Services' of the Republic of Latvia with respect to the Management Report, our responsibility is to consider whether the Management Report is prepared in accordance with the requirements of the 'Law on the Annual Reports and Consolidated Annual Reports' of the Republic of Latvia.
Based solely on the work required to be undertaken in the course of our audit, in our opinion:
In accordance with the 'Law on Audit Services' of the Republic of Latvia with respect to the Statement of Corporate Governance, our responsibility is to consider whether the Statement of Corporate Governance includes the information required in section 56.1, first paragraph, clause 3, 4, 6, 8 and 9, as well as section 56.2, second paragraph, clause 5, and third paragraph of the 'Financial Instruments Market Law' of the Republic of Latvia and if it includes the information stipulated in section 56.2 second paragraph, clause 1, 2, 3, 4, 7 and 8 of the 'Financial Instruments Market Law' of the Republic of Latvia.
In our opinion, the Statement of Corporate Governance includes the information required in section 56.1, first paragraph, clause 3, 4, 6, 8 and 9, as well as section 56.2, second paragraph, clause 5, and third paragraph of the 'Financial Instruments Market Law' of the Republic of Latvia and it includes the information stipulated in section 56.2 second paragraph, clause 1, 2, 3, 4, 7 and 8 of the 'Financial Instruments Market Law' of the Republic of Latvia.

Management is responsible for the preparation of the consolidated financial statements that Managemont is roopensioner with IFRSs as adopted by the European Union and for give a true and fair now management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do SO.
Those charged with governance are responsible for overseeing the Group's financial reporting process.
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could rrada or enroe expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.
As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the vve confinunicate with those onaryou will significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence and objectivity, and to with "relevant" ethical" roquirements" sand other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements matters that were of most of most of most of the key audit matters. We describe the matters in or the current perfod and are the regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be when, in extromory rare on because the adverse consequences of doing so would communicated in "our "roper" bogh the public interest benefits of such communication.
The responsible certified auditor on the audit resulting in this independent auditors' report is Armine Movsisjana.
KPMG Baltics SIA Licence No 55
Armine Movsisjana Chairperson of the Board Sworn Auditor Certificate No 178 Riga, Latvia 28 April 2017
This report is an English translation of the original Latvian. In the event of discrepancies between the two reports, the Latvian version prevails.
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR 2016 OAAC
| 2016 EUR |
CUITD EUR |
||
|---|---|---|---|
| Note 4 |
6 041 906 | 5 787 684 | |
| Income | 5 | (5 576 242) | (5 562 871) |
| Cost of services | 465 664 | 224 813 | |
| Gross profit | |||
| Administrative expenses | 6 | (628 801) | (526 071) |
| Other operating income | 7 | 325 914 | 275 912 |
| Other operating expenses | 8 | (204 979) | (715 022) |
| Operating loss | (42 202) | (740 368) | |
| Finance income | 202 | ||
| Net finance income | 202 | ||
| Loss before income tax | (42 000) | (740 368) | |
| Corporate income tax benefit | 0 | 44 753 | 114 426 |
| Profit/(loss) of the reporting year | 2 753 | (625 942) | |
| Other comprehensive income | |||
| Items that will never be reclassified to profit or loss | |||
| Revaluation of property, plant and equipment | 10 | (335 818) | |
| Changes in deferred tax from revaluation | 15 | 50 373 | |
| Adjustment in deferred tax | 15 | (36 752) | |
| Other comprehensive income for the year, net of | (322 197) | ||
| tax | |||
| Total comprehensive losses for the reporting year | (319 444) | (625 942) | |
| Loss for the reporting year attributable to: | |||
| Shareholders of the Company | 109 116 | (375 316) | |
| Non-controlling interest | (106 363) | (250 626) | |
| Comprehensive losses of the reporting year | |||
| Shareholders of the Company | (213 081) | (375 316) | |
| Non-controlling interest | (106 363) | (250 626) | |
Earnings/(loss) per share attributable to the shareholders of the Company (EUR per share)
| - Basic and diluted earnings/(loss) per share | (0.47) |
|---|---|
The accompanying notes on pages 19 to 44 form an integral part of these consolidated financial statements.
Board Member Chairperson of the Board Jānis Birks Juristmaks
Board Member Anatolijs Ahmetovs
28 April 2017
Chief Accountant Gunta Kaufmane
| 31.12.2016. | 31.12.2015. | ||
|---|---|---|---|
| Note | EUR | EUR | |
| ASSETS | |||
| Long-term investments | |||
| Fixed assets | 10 | 5 103 753 | 6 749 639 |
| Intangible assets | 10 | 8 719 | 9 396 |
| Total long term investments: | 5 112 472 | 6 759 035 | |
| Current assets | |||
| Inventories | 11 | 134 134 | 104 493 |
| Trade receivables | 12 | 220 704 | 200 787 |
| Other receivables | 127 525 | 18 163 | |
| Cash and cash equivalents | 13 | 2 872 519 | 1 739 013 |
| Total current assets: | 3 354 882 | 2 062 456 | |
| TOTAL ASSETS | 8 467 354 | 8 821 491 |
The accompanying notes on pages 19 to 44 form an integral part of these consolidated financial statements.
| Note | 31.12.2016. EUR |
31.12.2015. EUR |
|
|---|---|---|---|
| LIABILITIES AND EQUITY | |||
| Equity attributable to the shareholders of the Company |
|||
| Share capital | 14 | 1 120 000 | 1 120 000 |
| Long term investment revaluation reserve | 2 057 203 | 2 379 400 | |
| Other reserves | 63 819 | 63 819 | |
| Retained earnings | 2 772 776 | 2 663 660 | |
| 6 013 798 | 6 226 879 | ||
| Non-controlling interest | 25 | 760 722 | 892 194 |
| Total shareholders' equity: | 6 774 520 | 7 119 073 | |
| Liabilities | |||
| Long-term liabilities | |||
| Deferred tax liabilities | 15 | 390 878 | 681 252 |
| Deferred income | 16 | 421 247 | 449 174 |
| 812 125 | 1 130 426 | ||
| Short-term liabilities | |||
| Accounts payable to suppliers and contractors and other accounts payable |
17 | 852 783 | 541 760 |
| Deferred income | 16 | 27 926 | 30 232 |
| 880 709 | 571 992 | ||
| Total liabilities: | 1 692 834 | 1 702 418 | |
| TOTAL LIABILITIES AND EQUITY | 8 467 354 | 8 821 491 |
The accompanying notes on pages 19 to 44 form an integral part of these consolidated financial statements.
Chairperson of the Board
Jānis Birks
Board Member Anatolijs Ahmetovs
28 April 2017
Board Member Juris Imaks
Chief Accountant Gunta Kaufmane
| Attributable to the Shareholders of the Company | Non- controlling |
||||||
|---|---|---|---|---|---|---|---|
| Share capital |
Other reserves |
Revalua- tion reserve |
Retained earnings |
Total | interest | Total | |
| EUR | EUR | EUR | EUR | EUR | EUR | EUR | |
| Balance as at 31 December 2014 |
1 120 000 | 63 819 | 2 379 400 | 3 038 976 | 6 602 195 | 1 148 913 | 7 751 108 |
| Total comprehensive income/ loss for the |
- | (375 316) | (375 316) | (250 626) | (625 942) | ||
| year (loss) Profit/ of the reporting year |
- | (375 316) | (375 316) | (250 626) | (625 942) | ||
| Transactions with shareholders recorded directly in equity |
(6 093) | (6 093) | |||||
| Dividends | (6 093) | (6 093) | |||||
| Balance as at 31 December 2015 |
1 120 000 | 63 819 | 2 379 400 | 2 663 660 | 6 226 879 | 892 194 | 7 119 073 |
| Total comprehensive income/ loss for the |
|||||||
| year | - | (322 197) | 109 116 | (213 081) | (106 363) | (319 444) | |
| Profit/ (loss) for the reporting year |
109 116 | 109 116 | (106 363) | 2 753 | |||
| Other comprehensive income |
= | (322 197) | (322 197) | (322 197) | |||
| Transactions with shareholders recorded |
|||||||
| directly in equity | - | (25 109) | (25 109) | ||||
| Dividends | (25 109) | (25 109) | |||||
| Balance as at 31 December 2016 |
1 120 000 | 63 819 | 2 057 203 | 2772 776 | 6 013 798 | 760 722 | 6 774 520 |
The accompanying notes on pages 19 to 44 form an integral part of these consolidated financial statements.
Board Member Juris Imaks
Chairperson of the Board Jānis Birks
Bøard Member Anatolijs Ahmetovs
28 April 2017
Chief Accountant Gunta Kaufmane
| 2016 | 2015 | ||
|---|---|---|---|
| Note | EUR | EUR | |
| Cash flows from operating activities | |||
| Profit or loss before corporate income tax | (42 000) | (740 368) | |
| Adjustments for: | 10 | 390 225 | 470 373 |
| Depreciation | 10 | 5 345 | 10 605 |
| Amortization of intangible assets | 600 000 | ||
| Impairment losses | 8 | ||
| Loss from disposal of fixed assets | 8 | 175 051 | 90 868 |
| Amortisation of funds received from EBRD | 7 | 30 232 | 36 499 |
| 558 853 | 467 977 | ||
| Adjustments for: (Decrease)/ increase in trade receivables |
(129 279) | 60 686 | |
| Increase in inventories | (29 641) | (198) | |
| Decrease in accounts payable | 18 558 | (166 109) | |
| Net cash from operating activities: | 418 491 | 362 356 | |
| Cash flows from investing activities | |||
| Gain from sales of fixed assets | 1 704 358 | 118 000 | |
| Purchase of fixed assets | 10 | (964 234) | (260 055) |
| Net cash (used in) / generated from investing activities | 740 124 | (142 055) | |
| Cash flows from financing activities | |||
| Dividends to the non-controlling interest | 25 | (25 109) | (6 093) |
| Net cash used in financing activities | (25 109) | (6 093) | |
| Net increase of cash and cash equivalents | 1 133 506 | 214 208 | |
| Cash and cash equivalents at the beginning of the year | 1 739 013 | 1 524 805 | |
| Cash and cash equivalents at the end of the year | 13 | 2 872 519 | 1 739 013 |
The accompanying notes on pages 19 to 44 form an integral part of these consolidated financial statements.
Board Member Chairperson of the Board Juris Tmaks Jānis Birks rely Chief Accountant Board Member Gunta Kaufmane Anatolijs Ahmetovs 28 April 2017
The Joint Stock Company AS Latvijas Jūras medicīnas centrs (LJMC or the Company) was registered in the Republic of Latvia on 27 August 1996. The consolidated financial statements include the financial statements of the Company and those of Neirožu klīnika SIA (the Group). Since 21 May 2007, the shares of the Company have been traded on NASDAQ Riga Stock Exchange. The legal address of the Company is Patversmes iela 23, Riga, LV-1005, Latvia.
The companies of the Group provide healthcare services. AS Latvijas Jūras medicīnas centrs is a certified and advanced private medical facility, which provides in and out patient healthcare services to patients from all Latvia as well as foreigners. Neirožu Klīnika provides psychiatry and other services in a private clinic in Jurmala.
During 2016, the Group employed 380 employees on average (2015: 373).
The financial statements were approved by the Board of the Company on 28 April 2017.s
The shareholders of the Company have the right to approve or reject these consolidated financial statements or request the management to prepare new consolidated financial statements.
The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
These financial statements have been prepared in accordance with the International Financial Reporting Standards as adopted by the EU (IFRS). According to the approval procedure of the European Union, this note also reflects standards and interpretations, which are not approved for application in the European Union, as these standards and interpretations can have a significant impact on the financial statements of the Group in the future periods if they are approved.
The financial statements were prepared on the historical cost basis, except for the tangible assets presented under Land and buildings, which were measured using the revaluation method, as set out in (d) section of the note Accounting policies and measurement principles.
The preparation of financial statements in accordance with IFRS requires the management to make significant estimates and judgements. Also, in the preparation of the financial statements the management is required to make certain assumptions and judgements applying the accounting policies of the Group that impact the measurement of assets and liabilities, and the measurement of contingent liabilities as at the date of the consolidated financial statements and the amount of revenue and expenses during the reporting period. Even though these assumptions are based on the best experience and knowledge of the management, the actual results may be different.
The areas involving a higher degree of judgment are revaluation of fixed assets, determination of regularity of revaluation, management assumptions and calculations of the and recoverable amount of fixed assets, as well as recoverable amounts of inventories and classification of lease agreements, as described in the relevant notes.
The following guidance effective from 1 January 2016 did not have any impact on these financial statements:
A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after 1 January 2017, and have not been applied in preparing these financial statements. Those which may be relevant to the Group are set out below. The Group does not plan to adopt these standards early.
(i) IFRS 9 Financial Instruments (2014) (effective for annual periods beginning on or after 1 January 2018; to be applied retrospectively with some exemptions. The restatement of prior periods is not is permitted only if information is available without the use of hindsight. Earlier application is permitted.)
This Standard replaces IAS 39, Financial Instruments: Recognition and Measurement, except that it is still permitted to apply hedge accounting to IAS 39 and entities have an accounting policy choice between IFRS 9 and IAS 39.
Although the permissible measurement bases for financial assets - amortised cost, fair value through other comprehensive income (FVOCI) and fair value through profit and loss (FVTPL) - are similar to IAS 39, the criteria for classification into the appropriate measurement category are significantly different.
A financial asset is measured at amortized cost if the following two conditions are met:
In addition, for a non-trading equity instrument, an entity may elect to irrevocably present subsequent changes in fair value (including foreign exchange gains and losses) in OCI. These are not reclassified to profit or loss under any circumstances.
For debt instruments measured at FVOCI, interest revenue, expected credit losses and foreign exchange gains and losses are recognised in profit or loss in the same manner as for amortised cost assets. Other gains and losses are recognised in OCI and are reclassified to profit or loss on derecognition.
The impairment model in IFRS 9 replaces the 'incurred loss' model in IAS 39 with an 'expected credit loss' model, which means that impairment allowances will need to be recognised before a loss event.
IFRS 9 includes a new general hedge accounting model, which aligns hedge accounting more closely with risk management. The types of hedging relationships – fair value, cash flow and foreign operation net investment - remain unchanged, but additional judgement will be required.
The standard contains new requirements to achieve, continue and discontinue hedge accounting and allows additional exposures to be designated as hedged items.
Extensive additional disclosures regarding risk management and hedging activities will be required.
Based on the initial assessment, the Group believes that all financial assets classified as loans and receivables according to IAS 39 will remain accounted at amortised cost under IFRS 9.
It is not expected that the new expected credit loss model under IFRS 9 will significantly accelerate the recognition of impairment losses and lead to higher impairment allowances at the date of initial application.
The new Standard provides a framework that replaces existing revenue recognition guidance in IFRS. Entities will adopt a five-step model to determine when to recognise revenue, and at what amount. The new model specifies that revenue should be recognised when (or as) an entity transfers control over goods or services to a customer at the amount to which the entity expects to be entitled. Depending on whether certain criteria are met, revenue is recognised:
IFRS 15 also establishes the principles that an entity shall apply to provide qualitative disclosures which provide useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer.
The initial assessment of the potential impact of IFRS 15 on the Group's financial statements is still ongoing.
IFRS 16 supersedes IAS 17 Leases and related interpretations. The Standard eliminates the current dual accounting model for lessees and instead requires companies to bring most leases on-balance sheet under a single model, eliminating the distinction between operating and finance leases.
Under IFRS 16, a contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. For such contracts, the new model requires a lessee to recognise a right-of-use asset and a lease liability. The right-of-use asset is depreciated and the liability accrues interest. This will result in a front-loaded pattern of expense for most leases, even when the lessee pays constant annual rentals.
The new Standard introduces a number of limited scope exceptions for lessees which include:
Lessor accounting shall remain largely unaffected by the introduction of the new Standard and the distinction between operating and finance leases will be retained.
It is expected that the new standard, when initially applied, will have a significant impact on the Group's It is expected that the new standard, when intention of the statement of financial position assets.
financial statements, since it will require the Group to recognise on a lo financial statements, since it will require the Group acts as a lessee. See Note 20 for information
and liabilities arising from operating leases in which the Group acts as a on currently effective operating lease agreements.
(iv) Amendments to IFRS 2: Classification and Measurement of Share-based Payment Transactions (Effective (iv) Amendments to IFRS 2: Gassincation and Measurent of Ghere Back as may not and and on is a manufaction is permitted.)
The amendments clarify share-based payment accounting on the following areas:
The Group expects that the amendments, when initially applied, will not have a material impact on the financial The Group exposit that the Group does not enter into share-based payment transactions.
(v) Amendments to IFRS 10 and IAS 28 Sale or contribution of assets between an investor and its associate (V) Amendments (The effective date has not yet been determined by the IASB; however earlier adoption is permitted.)
The Amendments clarify that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business, such that:
It is expected that the amendments, when initially applied, will not have a material impact on the presentation of the financial statements of the Group.
(vi) Amendments to IAS 7 (Effective for annual periods beginning on or after 1 January 2017, to be applied prospectively. Earlier application is permitted.)
The amendments require new disclosures that help users to evaluate changes in liabilities arising from financing activities, including changes from cash flows and non-cash changes (such as the effect of foreign exchange gains or losses, changes arising for obtaining or losing control of subsidiaries, changes in fair value).
It is expected that the amendments, when initially applied, will not have a material impact on the Group's financial statements.
(vii) Amendments to IAS 12 – Recognition of Deferred Tax Assets for Unrealised Losses (effective for annual (vii) Amendments to IAS 12 – Recognition of Delened Yux Adoctorer of Brily. Earlier application is permitted.)
periods beginning on or after 1 January 2017; to be applied ret
The amendments clarify how and when to account for deferred tax assets in certain situations and clarify how The amendments clarity now and when to account for defered tax accessing the recognition of deferred tax
future taxable income should be determined for the purposes of assess assets.
It is expected that the amendments, when initially applied, will not have a material impact on the presentation It is expected that the amendments, when milally applied, will her some of the manner consistent with the Amendments.
(viii) Amendments to IAS 40 Transfers of Investment Property (Effective for annual periods beginning on or after 1 January 2018; to be applied prospectively.)
The amendments reinforce the principle for transfers into, or out of, investment property in IAS 40 Investment The amendments relimore the principle for tradels they or our on there has been a change in use of the Property to specity that such a transler sincies only when there is an actual change in use property. Based on the amendments a transfer is made when and there is evidence of there is evidence of the change in use. A change in management intention alone does not support a transfer.
It is expected that the amendments, when initially applied, will not have a material impact on the Group's financial statements as the Group has no investment property.
(ix) IFRIC 22 Foreign Currency Transactions and Advance Consideration (Effective for annual periods beginning on or after 1 January 2018).
The Interpretation clarifies how to determine the date of the purpose of determing the The merpretation claimes now to determine the related asset, expense or incoment or part of it), on the exchange Tate To use on Thilar Tooghildn'ty arising from the payment or receipt of advance deleoghillon in a foreign currency. In such circumstances, the date of the transation is the date on which an corisideration in a foreign our oney. In out in an-monetary liability arising from the payment or receipt of advance consideration.
The Group does not expect that the Interpretation, when initially applied, will have material impact on the financial statements as the Group uses the exchange rate on the transaction date for the initial recognition of the non-monetary asset or non-monetary liability arising from the payment or receipt of advance consideration.
Annual improvements to IFRSs 2014-2016 cycle were issued on 8 December 2016 and introduce two amendments to two standards and consequential amendments to other standards and interpretations that result in accounting changes for presentation, recognition or measurement purposes. The amendments on IFRS 12 Disclosure of Interest in Other Entities are effective for annual periods beginning on or after 1 January 2017 and amendments on IAS 28 Investments in Associates and Joint Ventures are effective for annual periods beginning on or after 1 January 2018; to be applied retrospectively. Earlier application is permitted.
These standards and interpretations are not expected to have a material impact on the Group's financial statements.
The Group plans to adopt these standards and interpretations as they become effective.
Subsidiaries are entities controlled by the Group. Control exists when the Group is exposed to oh as a right its Subsidianes are entitles controlled by the eroup store store and has the ability to affect those returns through its power over the investee.
Subsidiaries are fully consolidated from the date when control commences to the date when control ceases.
The subsidiary of the parent company:
| Country of | residence Number of shares | Subsidiary's equity | Subsidiary's profit/ (loss) |
|||
|---|---|---|---|---|---|---|
| EUR | 31.12.2016 31.12.2015 EUR |
2016 EUR |
2015 EUR |
|||
| SIA Neirožu Klīnika |
Latvia | 50.4% | 1 533 713 G | 398 860 | 1 203 097 | 662 |
The accounting policies of the subsidiary are amended when necessary to conform to the accounting policies of the Group.
All intra-Group transactions, balances and unrealized profit are eliminated upon consolidation. Unrealised All a Group eliminated unless there are indications that the underlying asset is impaired.
(C) Foreign currency transfaction
All amounts in these financial statements are expressed in the Latvian national currency – euro (EUR), the functional currency of the Group, unless otherwise stated.
Foreign currency transactions are translated into EUR according to currency exchange rates effective at the roler of transaction and determined by reconciliation of the European Central Bank and other central banks and which is published on the website of the European Central Bank.
As at the reporting date, all monetary assets and liabilities are translated into EUR according to exchange rates published on the website of the European Central bank. Non-monetary items of assets and liabilities are revalued to euros in accordance with the reference exchange rate published by the European Central Bank on the transaction date.
Exchange rates per EUR 1:
| 31.12.2016 | 31.12.2015 | ||
|---|---|---|---|
| USD | 1.0541 | 1.0887 |
Gain or loss resulting from payments under transactions executed in foreign currencies and the translation of monetary assets and liabilities denominated in foreign currencies is reflected in the profit and loss statement of the respective period.
Fixed assets is carried at cost or revalued amount less accumulated depreciation and impairment. The historical cost includes expenses directly connected with the acquisition of the asset group Buildings and land is revalued on a regular basis but no less often than once in five years.
The increase in value resulting from revaluation is recognized under Long term investment revaluation reserve The moreases that offset previous increases in the value of the same asset are charged against fair value and decreason that enset prounts charged to the income statement of the reporting year. On the revaluation date, the carrying amount of fixed assets is increased to match the revalued value.
All other fixed assets is carried at cost net of accumulated depreciation and accumulated impairment. Historical cost includes costs directly attributable to acquisition of fixed assets.
Subsequent expenses are added to the book value of the asset or recognized as a separate asset only where it is highly probable that future benefits related to this item would flow into the Company and expenses of this item can be estimated reliably.
Current maintenance and repair costs of fixed assets are recognized in the profit and loss statement as incurred.
Land is not subject to depreciation. For other assets, depreciation is calculated on a straightline basis over the entire useful life of the respective intangible asset and fixed asset in order to write their value or revalued value down to the estimated book value at the useful life based on the following rates:
| Years | |
|---|---|
| Buildings | 35-40 |
| Equipment and machinery | 3-5 |
The estimated carrying amounts and useful lives of assets are reviewed and, if necessary, adjusted at each reporting date.
In the event the carrying amount of fixed assets is higher than its recoverable amount, the value of the respective asset is immediately written down to its recoverable amount.
Profit or loss from the disposal of fixed assets is calculated as the difference between the carrying amount of the asset and income generated from sale, and charged to the profit and loss statement of the relevant period. When revalued Fixed assets is disposed, the amounts included in Revaluation reserve are charged to retained earnings.
Intangible assets include primarily software licenses and patents. The cost of software licences includes the expenses incurred to acquire the licences and the cost of software implementation. Intangible assets have definite useful lives. Intangible assets are carried at historical cost less accumulated amortisation. Amortisation is calculated starting from the day the asset is ready for use. Amortisation of intangible assets is calculated on a straight-line basis to write down their acquisition cost over the useful life. In general, intangible assets are amortised within 5 years.
All non-financial assets of the Group, except land, have definite useful lives. In addition, at each reporting assess All normancer associo of the Ordap, attopible assets subject to depreciation and other non-current, then the the or our abooooooo no tax asset, for indicators of impairment. If any such indicators exist, then the asset's recoverable amount is estimated.
An impairment loss is recognised if the carrying amount of an asset or its cash-generating unit exceeds its An inflaction of the result is the smallest identifiable asset group that generates cash flows that largely are independent from other assets and groups. Impairment losses are recognized in profit or loss. Imairment losses recognised for cash generating units are allocated to proportionally decrease the carrying amount of assets included in the CGU (set of CGU's).
The recoverable amount of an asset or cash generating unit is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU by which the estimated future cash flows are not adjusted.
In respect of long term assets, impairment losses recognized in prior periods are assessed at each reporting date for any indicators that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Any impairment loss reversed is only reversed to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.
Financial instruments of the Group comprise investments in trade and other receivables, cash and cash equivalents and trade and other payables. All financial assets are classified as receivables, and liabilities – as liabilities measured at amortised cost. Financial instruments of the Group are initially recognised at fair value plus directly attributable transaction costs. Financial assets are derecognized if the Group's contractual rights to the cash flows from the financial assets expire or if the Group transfers the financial asset to another party or substantially all risks and rewards of the asset are transferred. Financial liabilities are derecognized if the obligations specified in the Group contract expire or are discharged or cancelled.
Trade and other receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and other than held for trading. Trade receivables are stated at amortized cost less allowances for estimated irrecoverable amounts. Amortized cost is determined by applying the effective interest rate method, less impairment losses.
The effective interest rate is the rate that exactly discounts the estimated future cash payments and receipts through the expected life of the financial asset. The effective interest rate is calculated by the Group by through the expected ind of the financial terms of the financial instruments an impairment estimating future cash nows ochately evidence that the Group will not be able to collect all amounts due anowaries is recognificant financial terms. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganization, and default or delinquency in payments are considered uebtor will cincir bankrapto po ran or receivable is impaired. Allowances for doubtful receivables are calculated as a difference between the carrying amount of the asset and calculated future cash flow discounted at the as a ullierenoo betwoon the carrying amount of the asset is decreased and loss is recognised in profit or loss. Non-recoverable loans, trade or other receivables are written off.
Liabilities are initially recognised at fair value plus directly attributable transaction costs and subsequently recognised at amortised value using the effective interest rate.
Inventories are stated at the lower of cost and net realizable value. Cost is valued according to the FIFO method. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs necessary to complete the sale.
Cash and cash equivalents comprise cash on hand, current account balances and short-term deposits with terms shorter than 90 days and short-term highly liquid investments, which can be easily converted to cash when necessary and are not exposed to significant risk of change in value.
Ordinary shares are classified as equity. Dividend distribution to the Company's shareholders is recognized as a liability in the financial statements in the period in which the dividends are approved by the Company's shareholders.
The Group does not provide information on operating segments of the Group, as it does not perform separate accounting of segments. The operations of the Group are analysed on an aggregate basis, including in terms of management accounting.
Tax expenses for the reporting year comprise current tax and deferred tax calculated for the reporting year. Tax expenses for the reporting year complise canchised in comprehensive in comprehensive income or equity. In
Tax is recognised in profit or loss, except the printin is recog I ax is recognised in profit or loss, except the part which is roomprehensive income or equity.
this case, the tax is recognised, as appropriate, in the statement of comprehe
Corporate income tax is calculated in accordance with tax laws enacted at the reporting alte. The items Corporate income tax is calculated in accordance with in anagement on a periodic basis to deternine the reflection included in tax declarations are reviewed by the Oompany onlines are recognised to the extent they reflect payments planned to be made to tax authorities.
Corporate income tax is calculated in accordance with tax laws effective in the Republic of Latvia. The tax rate of 15% is set in the effective Law 'On Corporate Income Tax'.
Deferred tax in relation to all temporary differences between carrying amounts of assets and liabilities for Deferred tax in relation to all temporaly office for the liability method. The clability method. The cabulations of accounting and lax purposes is accrued to the full ontonio assected in the periods when the temporary differences reverse based on the tax rates effective at the reporting date.
Temporary differences arise primarily from different rates for amortisation of intengible assets and depreciation Temporary differences and revaluation of the rentision for and liability in foresons with recognized of fixed assets and revaluation, as well as non promonisans and and and and the reasonable certainty.
under assets on the statement of financial position when its recoverabil
Deferred tax assets and liabilities are offset by the Group only if it has a legally enforceable right on the same Delentu lax assets, and habilition at 6 encelate to income taxes levied by the same tax authority on the same carrent tax habilities and acoolo, and the which intend either to settle current tax liabilities and assets on a net basis.
An increase in deferred tax liabilities arising from revaluation of fixed assets is recorded as a reduction against a previous increase in the relevant long term investment revaluation reserve under equity. A decrease in deferred tax liabilities arising from depreciation of revalued items of fixed assets is recognised in profit or loss.
The Group makes social contributions into state health, pension and unemployment benefit systems in accordance with the rates set by the state which are effective in the reporting year, based on gross salary payments. The Group has no additional legal or constructive obligations to pay further contributions if the state funded pension scheme or a private pension plan is unable to honour its liabilities towards the employees. Contributions into the social security system and pension plans are expensed when the relevant salary payment is made.
Provision for unused vacations is calculated by multiplying the average employee's daily salary during the last six months of the reporting year and the number of accrued vacation days at the reporting date.
Revenue is recognised by the Group if the amount of reliably estimated, it is highly probably Revenue is recognised by the Group into the company and special criteria are met in relation to that future benefits related to this lien would into the calculouns are based by the Group on historical results.
each activity of the Group, as described below. The calculou each activity of the Group, as doothloon and specific provisions of each agreement.
Revenue from healthcare services or medical in- or out-patient services is recognised as the services pooided Revelue from healtheare services of who pays for the service. Prices for services paid by National based on an approved price inst rogardios of his in the manisation and funding of healthcare".
Health Service (NHS) are set in Cabinet Regulation No.1529 "Order of organisati
All revenue from services is recognized in the period when the services are provided.
Earnings per share are determined by dividing net profit or loss attributable to the shareholders of the Group by the weighted average number of shares during the reporting year.
Related parties represent both legal entities and private individuals related to the Group in accordance with the following rules.
a) A person or a close member of that person's family is related to a reporting group if that person:
Related party transaction - A transfer of resources, services or obligations between a reporting group and a related party, regardless of whether a price is charged.
Government grants are recognised only if there is reasonable assurance that the grants will be received and the Group will comply with the conditions attaching to them. Government grants are recognised as income over the periods necessary to match them with the related costs which they are intended to compensate, on a systematic basis, by recognising a respective receivable. Government grants related to assets are recognised at fair value under Deferred income, which are systematically recognised in the income statement over the remaining useful life of these assets.
The lease of fixed assets under which the risks and rewards of ownership are effectively retained with the lessor is classified as operating lease. Payments for operating lease (net of incentives granted by the lessor) are charged to profit or loss over the entire period of lease on a straight-line basis.
Finance income includes interest received on investments and profit or loss from foreign exchange fluctuations.
The Board has the overall responsibility for the establishing and supervision of risk management framework. The Group has identified the main risk factors and established a policy and mechanisms for controlling these factors. The following are defined as the main risks:
(a) Market risk - deterioration of the economic situation in the country, changes in the state and insurers' policy towards healthcare and its funding, competition, changes in public utilities rates, etc. can significantly impact the demand for services of the Group and its profitability.
Foreign currency risk - as the Group provides services only in the Republic of Latvia, it is not exposed to a significant foreign currency risk. The only open position as at 31 December 2016 in foreign currency was the current account in USD under cash and cash equivalent. As at 31 December 2016 it amounted to EUR 5 540 (31.12.2015: EUR 5 364). A decrease in the exchange rate of EUR to USD by 10% would increase (decrease) profit or loss and equity as at 31 December by EUR 554 in 2016 and EUR 536 in 2015. The analysis assumes that other variables, namely the interest rates, remain constant.
Interest rate risk - as the Group does not have assets and liabilities generating significant interest income, the cash flows and net results of the Group are mostly independent of changes in market interest rate risk is not considered to be material.
(b) Credit risk - The inability of insurance companies and patients to pay for the services provided by the Group in due time and in full amount. Most of the services are paid for within a short period of time before the provision of services or are funded by state or insurance providers, so credit risk is considered to be very low.
As at 31 December 2016, the Group's credit risk exposure to a single customer amounted to 78% of all trade receivables and 52% of total net sales (31.12.2015: 75% and 51% respectively) as all state paid services are funded through National Health Service. In relation to credit risk arising from other financial assets of the Group, which include cash and cash equivalents, the Group is exposed to credit risk which arises from the risk of counterparty default with the maximum exposure equal to the carrying amount of these instruments. The maximum credit risk exposure of the Group is EUR 3 220 748 or 38% of all assets (31.12.2015: EUR 1 957 963 or 22% of all assets). For more information on credit risk of the Group, refer to Note 12.
(c) Operational risk - the likelihood of incurring losses resulting from inadequate or unsuccessful internalion processes, activities of people and systems, or under the influence of extitude of possesses in the processes, activities of poople and of the medical services, organisation of the treatment on the first long term could lead to a decrease in income and even to claims of a financial nature.
(d) Liquidity risk – inability to satisfy legally enforceable claims in due time without substantial losses and inability to overcome unexpected changes in resources of the Group and/or market conditions due to an insufficient amount of liquid assets at its disposal. The Group has no external loans and it has significant financial resources to settle its liabilities.
Liquidity risk is managed by the Group according to the principle of prudence and a sufficient amount of cash is maintained. The liquidity ratio (defined as current assets over short-term liabilities) of the Group is 3.8 (31.12.2015: 3.6) and the quick ratio (defined as current assets less inventories over short-term liabilities) is 3.7 (31.12.2015: 3.4).
Liquidity reserves are monitored by the Group and forecasts are made based on expected cash flows. Most of the liabilities of the Group are current. The management believes that the Group will be able to provide a sufficient level of liquidity with its core operations and liquidity risk is not considered to be material.
Risk control measures involve: appropriate risk policies, investment planning and budget preparation and control rules, liquidity controls, organisation and control of treatment processes, control over compliance with sanitary requirements, improvement of staff qualifications, implementation of advanced technology, involvement of employees in risk assessment and control.
The objectives of the Group in capital management are to provide the ability of the Group to continue as a going concern while generating return to its shareholders and providing benefits to other stakeholders, as well as to maintain an optimal capital structure to reduce the cost of capital.
In order to determine an optimal capital structure, the management of the Group has the ability to make decisions on distributing dividends, capital return indicators or capital issue.
The capital structure indicator of the Group consists of liabilities, cash and cash equivalents and equity, comprising issued capital, retained earnings and reserves. The gearing ratio at the year-end was as follows:
| 31.12.2016 | 31.12.2015 | |
|---|---|---|
| EUR | EUR | |
| Liabilities | 1 692 834 | 1 702 418 |
| Cash | (2 872 519) | (1 739 013) |
| Net debt | (1 179 685) | (36 595) |
| Shareholders' equity | 6 774 520 | 7 119 073 |
| Debt to equity ratio | 25% | 24% |
| Net debt* to Equity ratio | -17% | -1% |
* Net debt calculated as total debt net of cash and cash equivalents.
IFRS 13 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable market data are obtained from independent sources. In the absence of observable market data the valuation approach reflects the assumptions of the Group regarding market conditions. This hierarchy requires the use of observable market data when available. The Group considers relevant and observable market prices in its valuations where possible.
The objective of the fair value measurement, even in inactive markets, is to arrive at a price at which an orderly transaction would take place between market participants to sell the asset or transfer the liability at the measurement date under current market conditions.
In order to arrive at the fair value of a financial instrument different methods are used: quoted prices or a valuation approach incorporating observable data based on internal models. These valuation methods are divided according with the fair value hierarchy in Level 1, Level 2 and Level 3.
The level in the fair value hierarchy within which the fair value of a financial instrument is categorized shall be determined on the basis of the lowest level input that is significant to the fair value in its entirety.
The classification of financial instruments in the fair value hierarchy is a two-step process:
Classifying each input used to determine the fair value into one of the three levels; 1.
Classifying the entire financial instrument based on the lowest level input that is significant to the fair value in its entirety.
Valuations in Level 1 are determined by reference to unadjusted quoted prices for liabilities in active markets where the quoted prices are readily available and the prices represent actual and regularly occurring market transactions on an arm's length basis.
Valuation techniques in Level 2 are models where all significant inputs are observable for the asset or liability, either directly or indirectly. Inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly (that is, as price) or indirectly (that is, derived from prices).
A valuation technique that incorporates significant inputs that are not based on observable market data (unobservable inputs) is classified in Level 3. Unobservable inputs are those not readily available in an active market due to market liquidity or complexity of the product. Level 3 inputs are generally determined based on observable inputs of a similar nature historic observations on the input or analytical techniques.
Cash and cash equivalents are included in Level 1. Cash and cash equivalents are financial assets with maturities below 3 months. The Group believes that the fair value of these financial assets matches their initial nominal value and the carrying amount at any future date.
The Group has no financial assets and liabilities categorised as Level 2.
Level 3 includes trade receivables, other payable to suppliers and contractors, loans and other financial commitments. The maturity for these financial assets and liabilities of the Group is largely below six months, so the Group believes that the fair value of these financial assets and liabilities matches their initial nominal value and the carrying amount at any future date.
The carrying amounts of liquid and short-term (maturity does not exceed three months) financial Instruments such as cash and cash equivalents, short-term deposits, short-term trade receivables and accounts payable to suppliers and contractors, approximates their fair value.
Land and buildings of the Group are measured at fair value. The valuation was based on a combination of the income and market approach. Given the definition of asset valuation set out in the international valuation standards it is assumed that the valuation uses observable data, which corresponds to a Level 3 valuation technique.
The most significant input data used in this approach is rent price per square meter and sales prices of similar properties adjusted by the most significant differences, for example, size of the property, location, etc.
| 4. REVENUE | 2016 EUR |
2015 EUR |
|---|---|---|
| Ambulatory medical services Services covered by insurance, including Paid ambulatory medical services Paid in-patient care |
5 450 279 505 057 280 812 224 245 |
5 130 369 426 370 230 239 196 131 |
| In-patient care Dental services Resident training Other income TOTAL |
59 099 24 008 3 463 6 041 906 |
191 136 19 520 20 018 271 5 787 684 |
The Group does not disclose information on distribution of net sales by lines of business in accordance with Regulation No. 1893/2006 (EK) of the European Parliament and European Council of 20 December 2006, with which the statistic classification of business activity NACE rev 2 is established, as its disclosure could have a severe negative impact on the interests of the Group.
| Remuneration | 2 601 300 | 2 495 693 |
|---|---|---|
| Depreciation | 395 570 | 480 978 |
| Medicines, medical materials | 698 511 | 687 765 |
| Compulsory state social security contributions | 595 486 | 571 294 |
| Utilities and maintenance | 240 622 | 260 076 |
| Non-deductible value added tax | 292 254 | 315 182 |
| Lease of equipment | 151 314 | 50 634 |
| Repair costs | 148 268 | 175 685 |
| Office items and equipment, other materials | 139 417 | 136 184 |
| Security | 23 809 | 20 461 |
| Medical examinations and other services | 58 401 | 43 640 |
| Changes in cost of accrued vacations | 3 632 | 64 490 |
| Patient catering expenses | 34 181 | 45 198 |
| IT expenses | 22 720 | 21 078 |
| Household consumption expenses | 22 685 | 26 562 |
| Real estate tax | 10 698 | 12 095 |
| Advertisement expenses | 33 349 | 29 865 |
| Office expenses | 10 912 | 13 657 |
| Insurance | 6 819 | 6 040 |
| Transport | 13 719 | 16 016 |
| Other expenses | 72 575 | 90 278 |
| TOTAL | 5 576 242 | 5 562 871 |
| 6. ADMINISTRATIVE EXPENSES | ||
| Remuneration | 353 742 | 376 148 |
| Compulsory state social security contributions | 81 371 | 86 976 |
| Communication expenses | 60 964 | 17 859 |
| Audit | 15 053 | 15 140 |
| Office maintenance | 13 739 | 9 663 |
| Bank services | 9 497 | 9 888 |
| Legal services | 79 909 | 900 |
| Other | 14 526 | 9 497 |
| TOTAL | 628 801 | 526 071 |
2016
2015
| Company Control Concession Company Controller | ||
|---|---|---|
| EUR | EUR | |
| Income from rent | 179 166 | 153 617 |
| Amortisation of funds received from EBRD | 30 232 | 36 499 |
| Refunded overpaid tax | 19 876 | 19 953 |
| Other income | 96 640 | 65 843 |
| TOTAL | 325 914 | 275 912 |
| 2016 | ZUTIO | |
|---|---|---|
| EUR | EUR | |
| Loss from impairment of land (see Note 10) | 600 000 | |
| Loss on disposal of fixed assets | 175 051 | 90 868 |
| Other expenses | 29 928 | 24 154 |
| TOTAL | 204 979 | 715 022 |
| TOTAL | (44 753) | (114 426) |
|---|---|---|
| Deferred tax | (276 753) | (114 426) |
| Current corporate income tax expense | 232 000 | |
| EUR | EUR | |
| 2016 | CUTO |
Current corporate income tax is different from the theoretical amount arrived at by applying the statutory rate of 15% to (losses) / profit of the Group before tax:
| Tax income | (44 753) | (114 426) |
|---|---|---|
| Effect from deferred tax corrections | (36 752) | |
| Effect of changes in other unrecognized temporary differences | (4 575) | (5 098) |
| Effect of non-deductible expenses | 2874 | 1 727 |
| Tax impact from: | ||
| Theoretical tax at 15% | (6 300) | (111 055) |
| Profit/(loss) before taxes | (42 000) | (740 368) |
| Intangible assets |
Buildings and land |
Equipment and machinery |
Other fixed assets |
Constructi on in progress |
Total fixed assets |
Total long- term investments |
|
|---|---|---|---|---|---|---|---|
| EUR | EUR | EUR | EUR | EUR | EUR | EUR | |
| Cost or | |||||||
| revalued value | |||||||
| 31.12.2014. | 73 849 | 7 010 889 | 3 601 362 | 535 540 | 526 606 | 11 674 397 | 11 748 246 |
| Impairment | (600 000) | (600 000) | (600 000) | ||||
| Additions | 11 687 | 34 835 | 50 948 | 162 585 | 248 368 | 260 055 | |
| Transferred | 429 740 | (429 740) | |||||
| Disposals | (4 145) | (52 296) | (24 292) | (42 896) | (156 571) | (276 055) | (280 200) |
| 31.12.2015 | 81 391 | 6 788 333 | 3 611 905 | 543 592 | 102 880 | 11 046 710 | 11 128 101 |
| Transferred | 130 782 | (130 782) | |||||
| Revaluation | (335 818) | (335 818) | (335 818) | ||||
| Additions | 4 668 | 44 212 | 23 293 | 892 061 | 959 566 | 964 234 | |
| Disposed | (2 046) | (1 900 000) | (160 374) | (26 422) | (2 086 796) | (2 088 842) | |
| 31.12.2016 | 84 013 | 4 683 297 | 3 495 743 | 540 463 | 864 159 | 9 583 662 | 9 667 675 |
| Depreciation | |||||||
| 31.12.2014 | 65 535 | 424 879 | 2 997 960 | 471 047 | 3 893 886 | 3 959 421 | |
| For 2015 | 10 605 | 134 632 | 295 425 | 40 316 | 470 373 | 480 978 | |
| Depreciation of disposals |
(4 145) | (24 292) | (42 896) | (67 188) | (71 333) | ||
| 31.12.2015 | 71 995 | 559 511 | 3 269 093 | 468 467 | 4 297 071 | 4 369 066 | |
| For 2016 | 5 345 | 137 311 | 214 905 | 38 009 | 390 225 | 395 570 | |
| Depreciation of disposals |
(2 046) | (24 948) | (156 722) | (25 717) | (207 387) | (209 433) | |
| 31.12.2016 | 75 294 | 671 874 | 3 327 276 | 480 759 | 4 479 909 | 4 555 203 | |
| Balance as at 31.12.2014 |
8 314 | 6 586 010 | 603 402 | 64 493 | 526 606 | 7 780 511 | 7 788 825 |
| Balance as at 31.12.2015 |
9 396 | 6 228 822 | 342 812 | 75 125 | 102 880 | 6 749 639 | 6 759 035 |
| Balance as at 31.12.2016 |
8 719 | 4 011 423 | 168 467 | 59 704 | 864 159 | 5 103 753 | 5 112 472 |
Land and buildings are measured by the Group using a revaluation policy. In 2016 and during the preparation Land and buildings are measured by the Group and constructions were valued by independent experts. The of these financial statements land, bullange and economication of the comparable transactions valuation was carned out by the mosperient of persons state of the assets: state of the assets, location of method and income netitions for use or sale of the asset, regulation of zone, business combination with other assets.
the asset, restrictions for use or sale of the asset, re the asset, restrictions for use of the assets approximates these assets approximates their carrying amount and liabilities. According to the management, the result of a downward revaluation of buildings and constructions after revaluation as at 31 December 2016. This previously recognised long-lem investment revaluation by EUR 355 of of the impact of dax. Additionally, in 2016, the management of the Group assessed the reserve, nel of the impact of delemed tax. Additions and concluded that the carrying amount of other trends in rent and sales process of administrative promises and the would be determined using the revaluation method as at the end of the reporting year.
The fair value of land and building was deternined by external, independent property values, having The Tall Value of Tand and building was "decommand recent experience in the location and category of the property being valued.
The land and building have been categorised as a Level 3 in the fair value hierarchy. The following table shows The land building have been bategonous aair value of core real estate items included in position "Buildings and land", as well as the significant unobservable inputs used:
| Type | Valuation technique | Significant unobservable inputs |
Inter-relation between significant unobservable inputs and fair value measurement |
|---|---|---|---|
| Buildings and land in the 852 122 located in Riga |
Fair value has been estimated based on the average of a fair amount of EUR values determined based on: Market comparison technique: The fair value was based on Price per m2 EUR 349 results of comparable sales of similar buildings Discounted cash flows technique: The model is based on discounted cash flows from rendering services |
Rent rate per m2 - 3.5 EUR - 5 EUR Capacity - 90% Capitalisation rate of 10% |
The fair value would increase (decreased) if the price per m2 was higher (lower). The estimated fair value would increase (decrease) if: Rent rate was higher (lower) Capacity percentage higher (lower) The capitalisation rate was lower (higher) |
| Significant | Inter-relation between significant unobservable inputs and fair value |
||
|---|---|---|---|
| Type | Valuation technique | unobservable inputs | measurement |
| Buildings and land in the 380 000 located in Riga |
Fair value has been estimated based on the average of a fair amount of EUR values determined based on: |
||
| Market comparison technique: The fair value was based on results of comparable sales of Price per m2 EUR 156 similar buildings |
The fair value would increase (decreased) if the price per m2 was higher (lower). |
||
| Discounted cash flows technique: The model is based on discounted cash flows from rendering services |
Rent rate per m2 - 1.5 EUR - 3.5 EUR Capacity 50% - 95% Capitalisation rate of 10% |
The estimated fair value would increase (decrease) if: - Rent rate was higher (lower) - Capacity percentage higher (lower) The capitalisation rate was lower (higher) |
|
| Buildings and land in the amount of EUR 2 052 536 |
Fair value has been estimated based on the average of a fair values determined based on: |
||
| located in Riga Market comparison technique: The fair value was based on results of comparable sales of similar buildings |
Price per m2 EUR 367 | The fair value would increase (decreased) if the price per m2 was higher (lower). |
|
| Discounted cash flows | Rent rate per m2 - 2 EUR - 5 EUR |
The estimated fair value would increase (decrease) if: |
|
| technique: The model is based on discounted cash flows from rendering services |
Capacity 90% Capitalisation rate of |
- Rent rate was higher (lower) - Capacity percentage higher (lower) |
|
| 9% | - The capitalisation rate was lower (higher) |
||
| Buildings and land in the amount of EUR 554 358 located in Riga |
Fair value has been estimated based on the average of a fair values determined based on: |
||
| Market comparison technique: Price per m2 EUR 309 The fair value would increase The fair value was based on results of comparable sales of similar buildings |
EUR | (decreased) if the price per m2 was higher (lower). |
|
| Discounted cash flows technique: The model is based on discounted cash flows from rendering services |
Rent rate per m2 - 1 EUR - 4.5 EUR Capacity 90% Capitalisation rate of 9.5% |
The estimated fair value would increase (decrease) if: - Rent rate was higher (lower) - Capacity percentage higher (lower) - The capitalisation rate was lower (higher) |
Had land and buildings not been revalued and presented at cost net of accumulated depreciation their carrying amounts would be as follows:
| 31.12.2016. EUR |
31.12.2015. EUR |
|
|---|---|---|
| Historical cost | 2 790 088 (1 005 937) |
3 050 890 (1 112 685) |
| Accumulated depreciation CARRYING AMOUNT |
1 784 151 | 1 938 205 |
In 2015, the Group recognised a loss of EUR 600 000 related to the decrease of the recoverable annumt of In 2015, the Group rooghlood a loos experienced a significant fall in real estate prices as a result of changes in the geopolitical situation and legislation regarding temporary residence permits o non-residents. There was . ClS in the geophilual situation and logliation rogal and the residents of Russia and former ClS
a significant decrease in demand for real estate in Jurmala from the dealine - The countries, which caused prices for luxury real estate properties in Jurmala to decline. The approximate recoverable amount of the said land plot is based on its fair value. The valuation was perfified recoverable annount of the cate No. 19) as at 31 December 2015 based on the market approach using the information on the latest sales transactions with similar property. Key assumptions determining fair value of information of the asset, location of the asset, restrictions for use or sale of the asset, regulation was and assels. State of the asset, lookien of the addities. In 2016, the real estate property in Jurmala was sold. Loss from the above sale was included in Other operating expenses (refer to Note 8).
| 31.12.2016. | 3 12 22015. | |
|---|---|---|
| EUR | EUR | |
| 124 505 | 102 926 | |
| Medicines | 9 629 | 1 567 |
| Other materials TOTAL |
134 134 | 104 493 |
| 12. TRADE RECEIVABLES | ||
| 31.12.2016. | 31.12.2015. | |
| EUR | EUR | |
| National Health Service | 116 497 | 131 229 |
| P. Stradiņa klīniskā universitātes slimnīca | 10 687 | |
| Insurance companies | 37 477 | 40 078 |
| Other institutions, companies and individuals | 56 071 | 31 581 |
| Due from related parties | 23 447 | |
| Doubtful debt allowance | (12 788) | (12 788) |
| TOTAL | 220 704 | 200 787 |
As at 31 December 2016 and 2015, the fair value of trade receivables approximated their carrying amount.
| 31.12.2016 | 31.12.2016 | 31.12.2015 | 31.12.2015 | |
|---|---|---|---|---|
| Gross debt | Allowance | Gross debt EUR |
Allowance EUR |
|
| EUR | EUR | |||
| Not overdue | 195 934 | 192 961 | ||
| Overdue 0 - 89 days | 10 483 | 361 | ||
| Overdue by more than 90 days | 27 075 | (12 788) | 20 253 | (12 788) |
| Total trade receivables | 233 492 | (12 788) | 213 575 | (12 788) |
| 31.12.2016 | 31.12.2015 | |
|---|---|---|
| EUR | EUR | |
| Current account, EUR | 2 828 881 | 1 571 473 |
| Current account, USD | 5 540 | 5 364 |
| Cash on hand, EUR | 6 865 | 4 320 |
| Cash in deposits, EUR | 30 849 | 157 568 |
| Cash in transit, EUR | 384 | 288 |
| TOTAL | 2 872 519 | 1 739 013 |
As at 31 December 2016 and 2015, the Group has an effective agreement with a bank for a term deposit with a seven day notice for cash withdrawal.
The share capital of the Group parent company as at 31 December 2016 is EUR 1 120 000 and it is divided into 800 000 shares with the nominal value of EUR 1.40.
The share capital of the Group parent company is held by the following shareholders:
| 31.12.2016 | 31.12.2015 | |||
|---|---|---|---|---|
| Number of | Holding % | Number of shares |
Holding % | |
| shares | ||||
| Ilze Birka | 140 000 | 17.50% | 140 000 | 17.50% |
| Mārtinš Birks | 140 000 | 17.50% | 140 000 | 17.50% |
| Ilze Aizsilniece | 70 565 | 8.82% | 70 565 | 8.82% |
| Guna Svarcberga | 82 917 | 10.36% | 82 880 | 10.36% |
| Jānis Birks | 102 388 | 12.80% | 102 388 | 12.80% |
| Adomas Navickas | 54 811 | 6.85% | 54 811 | 6.85% |
| Other shareholders (up to 5% | ||||
| shares per each) | 209 319 | 26.16% | 209 356 | 26.17% |
| Total | 800 000 | 100.00% | 800 000 | 100.00% |
| Share capital (EUR) | 1 120 000 1 120 000 |
All shares of the Company are name (publicly issued shares) shares with unlimited voting rights.
The Company offsets deferred tax assets and liabilities only when it is legally rightful to do so, and the deferred tax relates to the same tax administration.
Deferred tax arises from the following temporary differences between the carrying amounts of assets and liabilities and their tax.
Deferred tax relates to the following temporary differences:
| Assets/ (liabilities) 31.12.2014. EUR |
Recognise d in profit or loss in 2015, EUR |
Assets/ (liabilities) 31.12.2015. EUR |
Recognised loss in |
in profit or Recognised (liabilities) 2016, EUR 2016, EUR |
Assets/ in equity in 31.12.2016, EUR |
|
|---|---|---|---|---|---|---|
| Depreciation and revaluation | ||||||
| of fixed assets | (815 831) | 96 333 | (719 498) | 314 999 | 13 621 | (390 878) |
| Tax losses brought forward | 8 690 | 8 690 | (8 690) | |||
| Provisions | 20 153 | 9 403 | 29 556 | (29 556) | ||
| Net deferred tax liability | (795 678) | 114 426 | (681 252) | 276 753 | 13 621 | (390 878) |
Total movements in deferred tax:
| 2016 | 2015 | |
|---|---|---|
| EUR | EUR | |
| Deferred tax liabilities, beginning of the period | (681 252) | (795 678) |
| Changes in deferred tax recognized in the income statement | 276 753 | 114 426 |
| Recognised deferred tax changes from revaluation | 50 373 | |
| Adjustments to deferred tax in the revaluation reserve | (36 752) | |
| Deferred tax liabilities, end of the period | 390 878 | (681 252) |
| 16. DEFERRED INCOME | ||
| 31.12.2016 | 31.12.2015 | |
| EUR | EUR | |
| EBRD funding for purchase of fixed assets | ||
| The part of capital grants to be charged to profit or loss within one | ||
| year | 27 926 | 30 232 |
| The part of capital grants to be charged to profit or loss within 1 to | ||
| 5 years | 421 247 | 449 174 |
| TOTAL | 449 173 | 479 406 |
Income is amortised and included in the income statement for 2016 in the amount of EUR 30 232 (2015: EUR 36 499) (refer to Note 8).
| 31.12.2016 | 31.12.2015 | |
|---|---|---|
| EUR | EUR | |
| Accounts payable to suppliers and contractors | 136 363 | 74 587 |
| Unpaid salaries | 157 306 | 144 200 |
| Accrued liabilities for unused vacations. | 195 722 | 192 090 |
| Total financial liabilities | 489 391 | 410 877 |
| Tax liabilities | 360 395 | 128 253 |
| Prepayments received | 1 757 | 1 983 |
| Other liabilities | 1 240 | 647 |
| Total non-financial liabilities | 363 392 | 130 883 |
| TOTAL | 852 783 | 541 760 |
The carrying amounts of accounts payable to suppliers and contractors and other payables of the Group are not significantly different from their fair value, as the impact of the discount for short-term financial instruments is insignificant.
The management of the Company has no information on issued guarantees, current or pending legal proceedings and other contingent liabilities, which could have a material impact on the financial position of the Group. Since historically the Group has not experienced any significant losses due to malpractice claims, the management believes there is no necessity for provisions to be raised or insurance coverage for possible malpractice.
Agreements effective at the reporting date concerning capital expenditure not yet incurred:
Fixed assets
402 thousand
98 thousand
The Group has 25 effective operating lease agreements regarding equipment. According to this agreement, lease payments are the following:
265 222 EUR In 2017 In 2018-2020 1 326 109 EUR
In 2016, the Group performed transactions with related party through Board and Council members SIA Kodolmedicīnas klīnika, issuing invoices for rent payments in the amount of EUR 23 447. Other than remuneration to the management referred to in Note 23, the Group had no other transactions with related parties.
| 2016 EUR |
2015 EUR |
|
|---|---|---|
| Audit of the financial statements | 15 053 | 15 140 |
| 15 053 | 15 140 | |
2016
2015
| 23. REMUNERATION TO MANAGEMENT | |
|---|---|
| EUR | EUR | |
|---|---|---|
| Members of the Board | ||
| · remuneration | 70 248 | 87 296 |
| · compulsory state social security contributions | 16 259 | 16 593 |
| Members of the Council | ||
| · remuneration | 32 119 | 27 319 |
| · compulsory state social security contributions | 7 083 | 5 951 |
| Other members of the administration | ||
| · remuneration | 251 375 | 261 533 |
| · compulsory state social security contributions | 58 029 | 64 432 |
| 435 113 | 463 124 | |
| 24. AVERAGE NUMBER OF EMPLOYEES | ||
| 2016 | 2015 | |
| Average number of staff in the reporting year | 380 | 373 |
| Incl. Members of the Board | 3 | 3 |
| Members of the Council | 5 | 5 |
| Staff | 372 | 365 |
| 25. NON-CONTROLLING INTEREST | ||
| Movements in non-controlling interest in subsidiary SIA Neirožu Klīnika: | ||
| EUR | ||
| At the date of acquisition (October 2014) | 1 152 149 | |
| Share of loss of SIA Neirožu Klinika after acquisition | (3 236) | |
| Balance as at 31 December 2014 | 1 148 913 | |
| Share of loss of SIA Neirožu Klīnika in 2015 | (250 626) | |
| Dividends | (6 093) | |
| Balance as at 31 December 2015 | 892 194 | |
| Share of loss of SIA Neirožu Klīnika in 2016 | (106 363) | |
| Dividends | (25 109) | |
| Balance as at 31 December 2016 | 760 722 |
| 31.1722016 | 31.12.2015 | |
|---|---|---|
| EUR | EUR | |
| Non-controlling interest in SIA Neirožu Klinika | 49.6% | 49.6% |
| Long term assets | 11 386 | 256 186 |
| Current assets | 1 781 508 | 202 781 |
| Non-current liabilities | (10 853) | |
| Current liabilities | (259 181) | (49 254) |
| Net assets | 1 533 713 | 398 860 |
| Long-term assets fair value adjustment at acquisition | 1 399 918 | |
| Net assets after adjustments | 1 533 713 | 1 798 778 |
| Net assets attributed to the minority interest | 760 722 | 892 194 |
| Income | 438 164 | 438 568 |
| Profit/(loss) of the reporting year | 1 203 097 | 662 |
| Other comprehensive income | ||
| Total comprehensive losses for the reporting year | 1 203 097 | 662 |
| Changes in fair value adjustment including deferred tax effect | (1 417 539) | (505 956) |
| Total comprehensive losses for the reporting year | (214 442) | (505 294) |
| Losses of the reporting year attributable to minority interest | (106 363) | (250 626) |
| Other comprehensive income of the reporting year attributable to the | ||
| minority interest | ||
No significant subsequent events have occurred since the reporting year end that would materially impact the Group's financial statements for 2016.
Chairperson of the Board Board Member Jānis Birks Juris Maks Board Member Chief Accountant Anatolijs Ahmetovs Gunta Kaufmane
28 April 2017
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.